Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab versus verteporfin photodynamic therapy for myopic choroidal neovascularization
2010-021662-30Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2010
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ranibizumab and verteporfin in myopic maculopathy (MM) and Subretinal neovascularization (3 arms), sponsored by Novartis. Primary endpoints: Average best corrected visual acuity change from baseline over Months 1 to 3 and Non-inferiority of disease-activity retreatment versus stabilization-criteria retreatment over Months 1 to 6. Started Aug 2010; status: completed.
02
Drugs
ranibizumabverteporfin
03
Conditions
myopic maculopathy (MM)Subretinal neovascularization
Beyond the preview
Go deeper on 2010-021662-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021662-30.